Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Cash (2016 - 2025)

Historic Change in Cash for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$3.6 million.

  • Agios Pharmaceuticals' Change in Cash rose 9798.29% to -$3.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $12.9 million, marking a year-over-year increase of 20773.54%. This contributed to the annual value of $12.9 million for FY2025, which is 20773.54% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Change in Cash stood at -$3.6 million for Q4 2025, which was up 9798.29% from $11.8 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Cash ranged from a high of $1.8 billion in Q1 2021 and a low of -$918.9 million during Q2 2021
  • For the 5-year period, Agios Pharmaceuticals' Change in Cash averaged around -$1.9 million, with its median value being -$836500.0 (2025).
  • The largest annual percentage gain for Agios Pharmaceuticals' Change in Cash in the last 5 years was 2147055.87% (2021), contrasted with its biggest fall of 97284.89% (2021).
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Change in Cash stood at -$197.1 million in 2021, then surged by 108.53% to $16.8 million in 2022, then soared by 42.01% to $23.9 million in 2023, then crashed by 843.48% to -$177.5 million in 2024, then skyrocketed by 97.98% to -$3.6 million in 2025.
  • Its Change in Cash stands at -$3.6 million for Q4 2025, versus $11.8 million for Q3 2025 and $1.9 million for Q2 2025.